Eris Lifesciences Moves to Complete Swiss Parenterals Acquisition

In a disclosure made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Eris Lifesciences said its Executive Committee of the Board approved the allotment of 23,06,372 fully paid-up equity shares of face value Re 1 each at an issue price of ₹1,835.35 per share, including a premium of ₹1,834.35.

The preferential allotment was made to Mr Naishadh Shah through private placement for consideration other than cash, in accordance with Sections 42 and 62 of the Companies Act, 2013, and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The shares were issued in lieu of Eris Lifesciences acquiring 16,74,493 equity shares of Swiss Parenterals Limited, representing 30 percent of its total share capital, held by Mr Shah.

The company confirmed that the acquisition of the Swiss Parenterals shares was completed on January 16, 2026, resulting in Swiss Parenterals becoming a wholly owned subsidiary of Eris Lifesciences.

Eris Lifesciences noted that it had received in-principle approval from both BSE Limited and the National Stock Exchange of India Limited on January 9, 2026, for the preferential issue, as required under Regulation 28(1) of the SEBI LODR Regulations.

The newly allotted equity shares will rank pari passu with existing equity shares of the company in all respects, except for lock-in and transfer restrictions as prescribed under the SEBI ICDR Regulations and definitive transaction agreements.

Following the allotment, the paid-up equity share capital of Eris Lifesciences has increased from ₹13,62,16,891, comprising 13,62,16,891 equity shares of Re 1 each, to ₹13,85,23,263, comprising 13,85,23,263 equity shares.

The company stated that the newly issued equity shares will be listed on the NSE and BSE upon receipt of final listing approvals and will remain locked in as specified under Chapter V of the SEBI ICDR Regulations.